COVID-19 Vaccine Pipeline: Introduction
- COVID-19 is an infectious disease caused by the coronavirus. COVID-19 began its outbreak in Wuhan, China in December 2019. The World Health Organization (WHO) declared COVID-19 as Public Health Emergency of International Concern on January 30, 2020.
- COVID-19 is spreading rapidly across the globe and almost every country has reported notable number of cases as well as death due to this this infection
Read Report Overview: https://www.transparencymarketresearch.com/covid19-vaccine-pipeline-market.html
- Till date, the U.S. has recorded highest number of COVID-19 cases with count of more than one million active cases and more than 60,000 deaths. In Europe, more than 1.4 million active cases of COVID-19 have been reported as of April 30, 2020 with Italy being the worst affected country in the region. Italy has reported around 200,000 Covid-19 cases and more than 27,000 deaths.
- The most common symptoms associated with COVID-19 are fever, dry cough, tiredness, aches and pains, nasal congestion, sore throat; and diarrhea. In the beginning stages of the COVID-19 infections, the symptoms are very mild. According to the WHO, 1 out of every 5 COVID-19 patients becomes seriously ill and faces breathing problem.
- No perfect treatment or cure is available to treat the disease till date and lots of research and development activities are being carried out by leading players operating in the biopharmaceutical market place and all are expecting some positive outcomes very soon
- The WHO has facilitated and accelerated efforts on the development of COVID-19 vaccine on such a scale that was not ever seen before in history
- Healthcare experts estimate that the fast tracked vaccine development process could take around 12 to 18 months to successfully reach the market
Request Brochure of Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=77442
COVID-19 Vaccine Pipeline: Clinical Trial Phase 2/3
- The University of Melbourne and Murdoch Children’s Research Institute are testing Bacillus Calmette-Guerin (BCG) live-attenuated vaccine for COVID-19. According to a research article published in MedRxIV in April 2020, the people in countries with BCG vaccination program at childhood are less virulent to COVID-19 than that of people in countries without BCG vaccination program.
- Researchers at Radboud University Medical Center (The Netherlands) have launched the phase-3 BCG-CORONA trial on March 31, 2020 and plan to enroll 1,500 healthcare workers to receive the BCG vaccine or placebo
Clinical Trial Phase 2
- China-based biotech company Sinovac Biotech is developing COVID-19 vaccine candidate PiCoVacc. The company has claimed to have successfully tested the vaccine against COVID-19 in monkeys. The company is in talks with the World Health Organization to launch the phase-3 clinical trials in the region where the COVID-19 cases are rapidly spreading.
- Massachusetts-based biotech company Moderna has developed the mRNA-1273 COVID-19 vaccine candidate. The mRNA-1273 is currently in phase-2 stage of clinical trial pipeline study and the USFDA has awarded the fast track designation for this candidate.
- The China National Pharmaceutical Group (Sinopharm) is developing the inactivated vaccine candidate against COVID-19. The vaccine candidate has received the approval from the National Medical Products Administration and is currently in phase-2 of clinical trial pipeline studies.
Request for Covid-19 Impact Analysis – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=77442
Clinical Trial Phase 1
- China-based biotechnology company CanSino Biologics has used the adenovirus type 5 vector (Ad5) to develop novel COVID-19 vaccine. The preliminary safety data from phase-1 clinical trials is positive and it allowed the company to plan for phase-2 clinical trial studies.
- The Oxford university’s Jenner Institute in collaboration with AstraZeneca is developing the ‘ChAdOx1 nCoV-19′ coronavirus vaccine. The vaccine has shown the positive results on six rhesus macaque monkeys in March 2020. After the positive results from the initial trials on macaque monkey, the Oxford’s team is planning to test the vaccine on 6,000 people by the end of May 2020. If the clinical trials are successful in humans, then few million doses of the vaccine would be available by the end of September 2020.
- The Serum Institute of India has planned to collaborate with Oxford University for the manufacture of vaccine if clinical trials are successful. The Serum Institute of India can produce 5 million doses of vaccine per month for the first 6 months and after that, the company can scale up to 10 million doses per month.
- Inovio Pharmaceuticals is developing DNA vaccine INO-4800 against COVID-19. The Inovio Pharmaceuticals and the International Vaccine Institute (IVI) in association with Korea National Institute of Health (KNIH) are conducting phase 1/2 clinical trials in Korea.
- Pfizer Inc. and BioNTech have collaborated to develop COVID-19 vaccine candidate BNT 162. The BNT-62 is currently under phase 1/2 clinical trial study. The human trials are also started with BNT 162 in the U.S.
Enquiry Before Buying – https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=77442
Pre-clinical
- A lot of companies are developing COVID-19 vaccine candidates in preclinical studies. Some of companies having vaccine candidates in preclinical studies are Novavax, CureVac, Generex Biotechnology, Vaxart, Medicago, Takis Biotech, Altimmune, and Johnson and Johnson.
More Trending Reports by Transparency Market Research:
Hyaluronic Acid Products Market: According to the report, the global hyaluronic acid products market was valued at US$ 8.5 Bn in 2020. It is projected to expand at a CAGR of 7.1% from 2021 to 2028. Hyaluronic acid, one of the key components of the extracellular matrix (ECM), is a unique non-sulfated glycosaminoglycan that is well distributed across different types of tissues such as connective tissues, epithelial, and neural tissues.
Point-of-Care Diagnostics Market: According to the report, the global point-of-care diagnostics market was valued at US$ 34.1 Bn in 2020 and is projected to expand at a CAGR of 4.7% from 2021 to 2028. Point-of-care diagnostic test is carried out close to or near the patient location for analysis of health condition as well as presence of infectious diseases.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.”
Contact Us
Rohit Bhisey
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/
